Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1653
- Development stage
- Discontinued
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**mRNA-1653** is Moderna's investigational bivalent lipid nanoparticle-formulated mRNA vaccine designed to prevent respiratory disease caused by human metapneumovirus and human parainfluenza virus type 3. It contains two distinct mRNA sequences encoding the full-length membrane-anchored fusion glycoproteins of the two viruses; host-cell expression of these antigens is intended to induce binding and neutralizing antibody responses. Phase 1 studies in healthy adults and seropositive children evaluated intramuscular dosing, safety, reactogenicity, and immunogenicity. Adult data showed increased neutralizing antibody titers against both pathogens after vaccination. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35794943/?dopt=Abstract))
- Other names
- hMPV/PIV3 vaccine
02
Targets
HMPV F (Human metapneumovirus fusion protein)HPIV-3 F (Human parainfluenza virus 3 fusion protein)
Beyond the preview
Go deeper on mRNA-1653.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1653.